Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trickle Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (392)	1/19/2001 12:47:13 PM
From: tuck	Read Replies (1) \| Respond to of 1784

Fellow TrickleMavens, Disclosure update. In Reality, just sold some QGENF puts. This means my Mom and I have positions in the following stocks Trickle owns: QGENF, ABSC, NBSC, PBSC, PCOP, & GNSL Cheers, Tuck

To: keokalani'nui who wrote (392)	1/20/2001 12:46:40 PM
From: tuck	Read Replies (1) \| Respond to of 1784

Wilder, More APBiotech news: bio.com >>DNA Sciences and Amersham Pharmacia Biotech Collaborate to Develop Next Generation of DNA Analysis Technology PISCATAWAY, N.J. and FREMONT, Calif., Jan. 18 /PRNewswire/ -- DNA Sciences, Inc. and Amersham Pharmacia Biotech (APBiotech) announced today a collaboration to develop microchannel chip technology for the automated, high throughput analysis of nucleic acids. This platform has the potential to provide the next generation of DNA analysis technology, following the current generation, based on capillary electrophoresis, which was introduced by APBiotech to the market in 1998. The two companies will combine their expertise and intellectual property in microfabrication, engineering, reagent and applications development, and production scale sample processing to develop a robust high throughput system to be marketed exclusively by APBiotech to the life sciences and diagnostic markets. DNA Sciences will be paid licensing fees and will collect royalties from future product sales. APBiotech's capillary sequencing system, MegaBACE(TM), was the step change that enabled very high throughput sequencing such as that of the human genome. This new platform, developed with DNA Sciences' chip technology, could further cut time and cost in DNA analysis through miniaturization, speed and automation. ``We are committed to collaborative approaches that enable APBiotech to introduce innovative technologies that help customers to accelerate their research and discovery,'' said Dennis Harris, Vice President of Technology at APBiotech. ``Both companies have made progress independently in developing aspects of this novel technology. Joining our technological expertise and increasing development resources through this agreement will help us maximize the development of this platform for commercial applications.'' "This collaboration with APBiotech enables DNA Sciences to focus on strengthening our core genetics discovery effort to develop and commercialize clinical tests and therapeutics. We will receive value for our considerable investment in developing the technology and ensure that we gain early access to this technology,'' said Hugh Rienhoff, Jr., M.D., Chairman and Chief Executive Officer at DNA Sciences. ``We are pleased to engage in this collaboration with APBiotech and look forward to using the new platform for our own discovery efforts in the near future.'' APBiotech, the life sciences business of Nycomed Amersham plc (LSE: NAM; NYSE: NYE), is a leading provider of biotechnology systems, products and services for research into genes and proteins, for the discovery and development of drugs and for the manufacture of biopharmaceuticals. The customers for APBiotech's products and technology are pharmaceutical and biotechnology companies and research and academic institutions in North America, Europe, Latin America and Asia. DNA Sciences, Inc. is focused on identifying the genetic basis of disease susceptibility, disease progression and response to drug treatment. DNA Sciences, Inc. is based in Fremont, Calif., and was founded in May 1998.<< snip Cheers, Tuck